Healius transitions pathology arrangements with Ramsay Health Care subsidiaries
The new national framework covers thirteen hospitals and is expected to generate approximately $45m annual revenue.
See the latest news and media coverage for Healius. We track all announcements, press releases, and industry mentions in real time, all in one place.
Pathology and diagnostic services provider
healius.com.auLast updated
In short: Healius reported a 76% surge in EBIT for FY26, completed the $965 million sale of Lumus Imaging, and advanced the divestment of Agilex.
The new national framework covers thirteen hospitals and is expected to generate approximately $45m annual revenue.
Group EBITDA expected between $259m and $264m; exploring sale of Agilex Biolabs; Federal Budget offers no new pathology funding.
John Mattick ceased as director on 31 March 2026. He holds 4,136 ordinary shares directly and interests in 250,181 shares indirectly.
Group revenue rises 3.8% to $688.1M, EBITDA up 13.1% to $122.2M, EBIT $7.9M from prior loss. Pathology revenue up 3.5%, Agilex up 16%.
Buyout firms sound out takeover target Healius The Australian | Private Equity on AlphaMaven. | AlphaMaven...
Healius Ltd (ASX:HLS) delivers strong earnings growth despite Fair Work headwinds, with FY27 guidance in line with consensus and a path to positive cash flow.
DataRoom earlier reported that the sale process was gathering momentum, with a field of six or seven parties putting forward indicative bids. DataRoom understands that...
Sellside adviser UBS issued more than 30 investment memorandums over the weekend and called for non-binding offers before the end of July.
Track Healius and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.
Browse news for competitors to Healius and other trending companies.